Stocks:
5,167
ETFs:
2,288
Exchanges:
11
Market Cap:
$62.23T
24h Vol:
$11.14B
Dominance:
MSFT:4.87%
Stocklytics Platform
Instrument logo  LNTH
Lantheus Holdings
LNTH
89 / 100
High Quality
High Growth
$64.41arrow_drop_up2.12%$1.34

Performance History

Stocklytics logo
Key Stats
Open$63.02
Prev. Close$63.07
EPS4.65
DividendNon-Dividend
Next Earnings Date-
Dividend Yield %-
Market Cap$4.32B
PE Ratio13.85
LOWHIGH
Day Range62.59
65.54
52 Week Range50.20
100.85
Ratios
P/B Ratio5.11
Revenue$1.29B
Operating M. %42.45%
Earnings$326.66M
Earnings Growth %1,063.86%
EBITDA Margin %43.66%
ROE %51.73%
EPS4.65

Score Breakdown

Welcome to Stocklytics

Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.

89vs 54. Market Avg.

All Score 89 / 100 is to help users identify stocks that trade at a low value relative to their fundamentals. Suitable for value investors such as Warren Buffet.

LNTHMARKET
Value6340
Quality8640
Ownership117
Growth7845
Dividends-38
check_circle

Lantheus Holdings 's Price growth average in the last 3 years of 61.69% is great compared to market average of 5.62%. This indicates LNTH could be a good value stock.

Financial Forecast

AI Price Prediction

line chart placeholder

Analyst Ratings

info
Analyst ratings for this stock instrument are based on analysts' assumptions and should not be solely relied upon for financial decisions.

Correlated Companies

PRICE$731.65
24H (%)arrow_drop_down1.88%
24H ($)-$14.03
MARKET CAP$695.32B
PRICE$487.37
24H (%)arrow_drop_up0.24%
24H ($)$1.19
MARKET CAP$452.88B
PRICE$148.53
24H (%)arrow_drop_down0.68%
24H ($)-$1.03
MARKET CAP$359.34B
PRICE$127.00
24H (%)arrow_drop_up0.09%
24H ($)$0.12
MARKET CAP$321.39B

About Lantheus Holdings (LNTH)

Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine; Xenon-133 to assess pulmonary function; Neurolite to identify the area within the brain where blood flow has been blocked or reduced due to stroke; and Cardiolite, an injectable Tc-99m-labeled imaging agent. The company also offers AZEDRA, a radiotherapeutic therapy; Automated Bone Scan Index that calculates the disease burden of prostate cancer by detecting and classifying bone scan tracer uptakes as metastatic or benign lesions using an artificial neural network; RELISTOR for opioid-induced constipation; and PYLARIFY for visualization of lymph nodes, bone, and soft tissue metastases to determine the presence or absence of recurrent and/or metastatic prostate cancer. It also develops flurpiridaz to assess blood flow to the heart; 1095, a PSMA-targeted iodine-131 labeled small molecule; PNT2002 for pre-chemotherapy patients; PNT2003, an SSTR therapy that treats patients with SSTR-positive neuroendocrine tumors; and PYLARIFY AI, an AI-based medical device software to perform standardized quantitative assessment of PSMA PET/CT images in prostate cancer. The company serves hospitals, independent diagnostic testing facilities, government facilities, integrated delivery networks, radiopharmacies, clinics, distirbutors, and group practices. It has strategic partnerships with NanoMab Technology Limited; Bausch Health Companies, Inc.; GE Healthcare Limited; and FUJIFILM. The company was founded in 1956 and is based in Bedford, Massachusetts.

Sector
Healthcare
Industry
Drug Manufacturers—Specialty & Generic
CEO
Ms. Mary Anne Heino
Headquarters
Bedford
Employees
698
Exchange
NASDAQ
add Lantheus Holdings  to watchlist

Keep an eye on Lantheus Holdings

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

search
help
What is the 52-week high and low for Lantheus Holdings (LNTH)?

For Lantheus Holdings (LNTH), the 52-week high is $100.85, which is 54.77% from the current price. The 52-week low is $50.2, the current price is 29.8% above the 52-week low. This gives investors an insight into the stock's volatility and price range over the past year.

help
Is Lantheus Holdings (LNTH) a growth stock?

Lantheus Holdings (LNTH) has shown an average price growth of 61.69% over the past three years. It has received a score of 93 out of 100 based on the Stocklytics formula. The interpretation of this score in terms of classifying Lantheus Holdings as a growth stock may vary, considering it is one of many factors investors might evaluate, including market trends, financial performance, and future prospects of the company.

help
What is Lantheus Holdings 's (LNTH) price per share?

The current price per share for Lantheus Holdings (LNTH) is $65.16. The stock has seen a price change of $0.75 recently, indicating a 1.16% change. This reflects the stock's recent market performance and investor sentiment.

help
What is Lantheus Holdings (LNTH) stock price performance year to date (YTD)?

As of the latest data, Lantheus Holdings (LNTH) has a year-to-date price change of 3.33%. Over the past month, the stock has experienced a price change of 10.42%. Over the last three months, the change has been 27.6%. Over the past six months, the figure is -4.89%. Looking at a longer horizon, the five-year price change stands at 161.06%.

help
Is Lantheus Holdings (LNTH) a profitable company?

Lantheus Holdings (LNTH) has a net income of $326.66M, which represents the company's total earnings after all expenses have been deducted from revenues. The gross margin of 54.73% indicates the percentage of revenue that exceeds the cost of goods sold, and the operating margin of 42.45% reflects the percentage of revenue remaining after covering variable production costs, highlighting the efficiency of the company's core operations. Total revenue stands at $1.3B, with a revenue growth rate of 38.65%, providing insight into the company's sales performance and growth. The gross profit is $709.54M. Operating income is noted at $364.64M. Furthermore, the EBITDA is $444.18M.

help
What is the market capitalization of Lantheus Holdings (LNTH)?

Lantheus Holdings (LNTH) has a market capitalization of $4.32B. The average daily trading volume is 690.85K, indicating the stock's liquidity and investor engagement.

News

email

Sign up for our newsletter

Join our exclusive community of over one million investment enthusiasts and receive our free newsletter filled with analysis, news, and updates every weekday.

Approach investments with caution like a driver who slows down on a curvy road.